Source comparison
Thymosin Alpha-1 vs Alternative Peptides: Route Comparison
Thymosin Alpha-1 <1% (enzymatic degradation) ~100% (direct lymphatic absorption) Subcutaneous 1.6mg twice weekly No (available as research compound only) Semaglutide (GLP-1) <1% (requires SNAC permeation enhancer) ~89% at steady state Both routes FDA-approved;
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- <1% (enzymatic degradation)
- ~100% (direct lymphatic absorption)
- Subcutaneous 1.6mg twice weekly
- No (available as research compound only)
- Semaglutide (GLP-1)
- <1% (requires SNAC permeation enhancer)
- ~89% at steady state
- Both routes FDA-approved; oral requires 14× higher dose
- Yes (Rybelsus oral, Ozempic subcutaneous)
- Insulin
- 0% (complete gastric degradation)
- 55–77% depending on formulation
- Subcutaneous or intravenous only
- Yes (multiple formulations)
- BPC-157
- Unproven (no Phase 3 trials exist)
- Experimental subcutaneous in animal models
- No
- Tesamorelin (GHRH analog)
- 0% (pepsin cleavage within minutes)
- ~100% (approved for HIV lipodystrophy)
- Subcutaneous 2mg daily
- Yes (Egrifta)